Therapy Areas: Central Nervous System
Moleculin Biotech reveals additional preliminary data from Phase one WP1066 clinical trial
14 October 2020 -

Moleculin Biotech Inc, (Nasdaq: MBRX), a clinical stage pharmaceutical company, has revealed additional preliminary data from the Phase one clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, in patients with glioblastoma, it was reported on Tuesday.

This move supports the progression of the trial to the fourth and final dose escalation cohort. The company has completed treatment of three patients in the third cohort at a dose level of 8mg/kg with no adverse events related to the product and the study will now proceed to the next higher dose of 16mg/kg.

Walter Klemp, Moleculin chairman and CEO, said, 'On the heels of our recent positive announcement regarding the progress of the paediatric brain tumour trial of WP1066, we are pleased to also report on the progress of the adult GBM clinical trial for the same drug candidate. The trial in adults has been important in leading the way to establishing a safe and tolerable human dose level for what we believe is a first-in-class compound that crosses the blood-brain barrier and is being developed for the treatment of central nervous system malignancies. In animal models, WP1066 has been shown to stimulate immune responses that successfully modulate oncogenic transcriptional activity in tumour cells and repress their ability to drive tumour growth.'

Login
Username:

Password: